Autoantibody Screens
We offer 3 microarrays and bead-based assays. Whether you want test your sample against ~20,000 targets or a more focused assay of 128 known autoantigens - we have you covered!
Increasing needs in Oncology for easily measurable biomarkers: Cancer immunotherapy is experiencing a meteoric rise, with >2500 clinical trials (in the past decade alone) testing a wide spectrum of immune checkpoint blockades (ICB), adoptive cell therapy (ACT) including CAR-T and CAR-M, and cancer vaccines (CV)(1-10). Besides biomarkers for diagnosis/surveillance of cancer onset /recurrence, prediction of response/resistance to treatment, and prognostication, this emerging chapter in Oncology demands a new armamentarium of biomarkers, including:
- Blood and Tissue biomarkers that predict who might respond best to ICB, ACT, CV, etc.
- Blood and Tissue biomarkers that help researchers identify targets to improve ICB, ACT, CV, etc.
- Biomarkers for early detection of adverse events such as CRS/ICANS, as we have reviewed (11)
- Markers that uniquely define the tumor and infiltrating leukocytes, for use as biomarkers or targets
- Novel tumor-associated antigens that can be used as targets for CV.
Rationale for the proteomic platforms offered: To meet the above needs, we offer the most comprehensive proteomic screens (Somascan platform that screens 11,000 proteins), and focused customizable high throughput proteomics for clinical trials (Olink platforms for screening 48, 96 or 1000 targets). Autoantibodies can also be biomarkers; hence we offer the largest autoantibody screen against linear epitopes (Platform from CDI Labs incorporates 21,000 targets), and conformational epitopes (n = 2000 targets; Platform from Sengenics). As opposed to mass spectrometry-based proteomics, targeted proteomics detects even low abundance biomarkers, with quantitation. The platforms offered at CIBC include:
11,000-plex proteomics (Somascan platform that allows detection of 11,000 proteins in body fluids)
Focused proteomic panels (using Olink Proximity Ligation Assay): These include 15 different disease-specific panels that interrogate 48, 96 or 1000 proteins, as well as PI-designed 15-21-plex custom panels, capable of handling hundreds of samples, using just 1 ul volumes.
21,000-plex protein arrays: Array platform from CDI allows specificity testing of autoantibodies and ligands against the entire human proteome.
2,000-plex conformational ligand profiling (Sengenics platform with natively folded conformational proteins, useful for discovering novel autoantibodies and ligands against functional human proteins)
Contact us for assay requests, research consultations, and exclusive pricing today!
t: 713-743-3261 e: cibc@central.uh.edu
a: 3517 Cullen Blvd, Room 2018, SERC, Biomedical Engineering Dept., Houston, TX, 77204
Texas Based cancer researchers will be charged a discounted fee. See new CIBC price list
Contact: Dr.Ma (yma29@central.uh.edu)
This CPRIT CIBC Core facility is supported by a CPRIT grant (CPRIT Cancer Immunotherapy Biomarker Core Facility Award RP250585).